European Commission Approves Bristol-Myers Squibb Company's ORENCIA(R) (abatacept) in Combination with Methotrexate for Children with Moderate to Severe Polyarticular Juvenile Idiopathic Arthritis (pJIA)

PARIS--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) today announced that on 20 January 2010, the European Commission approved ORENCIA® (abatacept) in combination with methotrexate for the treatment of moderate to severe active polyarticular juvenile idiopathic arthritis (pJIA) in paediatric patients six years of age and older who have had an insufficient response to other DMARDS, including at least one TNF inhibitor.1

Back to news